Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein may predict seizure return, study halted early

NCT ID NCT02424123

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether measuring a protein called S100B in the blood right after a first seizure could help predict if someone will have more seizures within a year. The researchers planned to follow 37 adults for one year, but the study was stopped early. The goal was to find a simple blood test to guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

37 people

The number who actually took part.

Started

Oct 2016

Finished

Jul 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is composed of patients between 18 and 60 years of age, of both sexes, recruited during consultations for a first epileptic seizure at the emergency department of Nîmes and Marseille Hospitals (CHRU).

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient has been correctly informed. * The patient must have given his informed and signed consent. * The patient must be insured or beneficiary of a health insurance plan. * The patient is at least (≥) 18 years old and less than (\<) 60 years old. * The patient has experienced a first generalized, epileptic seizure (patients with partial onset and secondary generalization can also be included). * The seizure has occurred less than 24 hours ago. Exclusion Criteria: * The patient is participating in another study that may interfere with the results or conclusions of this study. * Within the past three months, the patient has participated in another study that may interfere with the results or conclusions of this study. * The patient is in an exclusion period determined by a previous study. * The patient is under judicial protection. * The patient refuses to sign the consent. * It is impossible to correctly inform the patient. * The patient is pregnant or breast-feeding (MRI contraindicated). * Patient has a previous abnormal brain imaging (MRI). * Patient has abnormal biological tests for toxicology (alcohol, cocaine and cannabis tests), blood ionogram (hyponatremia \<130mM), liver enzymes (\>5N), inflammatory syndrome (elevated C-reactive protein).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epilepsy Seizures, epileptic

Contacts and locations

Locations

  • APHM - Hôpital Nord

    Marseille, 13915, France

  • CHRU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.